PACB Pacific Biosciences of California Inc.

PacBio to Present at Upcoming Investor Conferences

PacBio to Present at Upcoming Investor Conferences

MENLO PARK, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences:

  • Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025, at 2:30 PM ET in Boston, MA
  • Morgan Stanley 23rd Annual Global Healthcare Conference on Wednesday, September 10, 2025, at 12:20 PM ET in New York, NY

Live webcasts of the events can be accessed at the company’s investors page at investor.pacificbiosciences.com. A replay of the webcasts will be available for at least 30 days following the event.

About PacBio

PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit and follow @PacBio.

PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.

Contacts

Investors:

Todd Friedman

Media:



EN
06/08/2025

Underlying

PACBPacific Biosciences of California Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pacific Biosciences of California Inc.

 PRESS RELEASE
Free
PACB Pacific Bioscie...

PacBio Announces Fourth Quarter and Full Year 2025 Financial Results

PacBio Announces Fourth Quarter and Full Year 2025 Financial Results MENLO PARK, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2025. Fourth quarter and full year results:  Q4 2025Q4 2024FY 2025FY 2024Revenue (in millions)$44.6$39.2$160.0$154.0Consumable revenue (in millions)$21.6$18.8$82.0$70.3Instrument revenue (in millions)$17.3$15.3$53.8$65.8Service and other revenue (in millions)$5.7$5.1$24.2$17.9RevioTM system placements21236197VegaTM system placements4271407Annualized Revio pul...

February 12, 2026 1 EN
 PRESS RELEASE
Free
PACB Pacific Bioscie...

PacBio Joins iHope Initiative as First Long-Read Genomic Sequencing Pa...

PacBio Joins iHope Initiative as First Long-Read Genomic Sequencing Partner Integration of HiFi Long-Read Whole-Genome Sequencing Expands the Collective Capabilities of iHope’s Global Rare Disease Network MENLO PARK, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced a collaboration with iHope, a global rare disease genomics program of Genetic Alliance, to integrate PacBio’s HiFi® long-read whole-genome sequencing into iHope’s international network. iHope operates the world’s largest eq...

February 12, 2026 1 EN
 PRESS RELEASE
Free
PACB Pacific Bioscie...

PacBio Completes Sale of Short-Read Sequencing Assets

PacBio Completes Sale of Short-Read Sequencing Assets MENLO PARK, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the completion of the sale of select intellectual property and other assets related to PacBio’s short-read DNA sequencing technology and related clustering, sequencing reagent, and detection technologies to Illumina, Inc. PacBio received $48.1 million in net cash proceeds from the transaction. Under the terms of the agreement, Illumina assumed certain liabilities and gr...

February 2, 2026 1 EN
 PRESS RELEASE
Free
PACB Pacific Bioscie...

PacBio to Report Fourth Quarter and Full Year 2025 Financial Results o...

PacBio to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026 MENLO PARK, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter and full year 2025 financial results on Thursday, February 12, 2026, at 5:00 pm Eastern Time. The call will be webcast and may be accessed at PacBio’s website at . Date: Thursday, February 12, 2026, at 5:00 pm ET (2:00 pm PT) Listen live via internet or replay: Toll-free: 1-888-349-0136 International: 1-412-317-0459 About PacBio ...

January 27, 2026 1 EN
 PRESS RELEASE
Free
PACB Pacific Bioscie...

PacBio Announces Plans for Collaboration With n-Lorem Foundation and E...

PacBio Announces Plans for Collaboration With n-Lorem Foundation and EspeRare to Advance Precision Therapies for Rare Genetic Diseases The planned collaboration highlights the role of complete genome resolution in scaling n-of-1 therapeutic models MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today announced plans to pursue a strategic collaboration with the n-Lorem Foundation and EspeRare that we believe will position long-read whole-genome sequencing as enabling infrastructure to support the...

January 12, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch